Michael Straiko, MD
Cornea and External Diseases Specialist · Portland, ORNPI 1013127075
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,538 of the $15,008 with a category attached, or 76.9%. Glaukos Corporation accounts for 76.7% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $11,658, more than ten times the $800 reported in 2019.
Across 37 payments — averaging $405.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$12K
- W. L. Gore & Associates, Inc.$2K
- Kowa Pharmaceuticals America, Inc.$600
- Johnson & Johnson Surgical Vision, Inc.$244
- Biotissue Holdings Inc.$104
- Oyster Point Pharma, Inc.$94
- plus $100 from 2 others
Across 51 payments — averaging $1499.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$71K
- Glaukos Corporation$5K
What the payments were for
- Consulting fees$11,53877%
- Speaking & faculty fees$6004%
- Travel & lodging$1,46010%
- Food & beverage$1,3939%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 17 | $11,517 |
| W. L. Gore & Associates, Inc. | 3 | $2,350 |
| Kowa Pharmaceuticals America, Inc. | 1 | $600 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $244 |
| Biotissue Holdings Inc. | 3 | $104 |
| Oyster Point Pharma, Inc. | 1 | $94 |
| Rxsight Inc | 2 | $58 |
| Bausch & Lomb Americas Inc. | 2 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epioxa$9,188
- Product in Development$2,350
- Travoprost Intraocular Implant - iDose$1,737
- KXL System$110
- KXL1B-CE-marked KXLsystem$110
How this compares
Too few cornea and external diseases specialist providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorometholone | 458 | $42,545 |
| XiidraLifitegrast | 32 | $27,198 |
| Prednisolone Acetate | 490 | $19,903 |
| RestasisCyclosporine | 17 | $16,673 |
| MieboPerfluorohexyloctane/Pf | 12 | $8,923 |
| Cyclosporine | 13 | $6,082 |
| ValacyclovirValacyclovir Hcl | 76 | $4,476 |
| Ofloxacin | 228 | $2,454 |
| Loteprednol Etabonate | 15 | $2,113 |
| Doxycycline Monohydrate | 51 | $1,430 |
| Doxycycline Hyclate | 36 | $1,349 |
| MoxifloxacinMoxifloxacin Hcl | 59 | $1,163 |
| ErythromycinErythromycin Base | 30 | $381 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 24 | $296 |
| Acyclovir | 22 | $208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $42 | $36,12144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Oregonon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Portland
- Mark TerryPortland$104K
- Winston ChamberlainPortland$27K
- John ClementsPortland$3K
- David DemillPortland$1K
- Roma PeganyPortland$724
- Afshan NanjiPortland$410
- Ashlin JoyePortland$368
- Matthew OlivaMedford$949
- John WellingMedford$757
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.